Pharmaceuticals

$ZVRA Reports Q4 2025 Revenue Growth Amidst Pipeline Advancements

Stock market news /

Zevra Therapeutics, Inc. (ZVRA) reported its financial results for the fourth quarter and full year ended December 31, 2025, highlighting significant revenue growth and continued progress in its rare disease pipeline. The company posted **net product revenue of $15.2 million** for Q4 2025, primarily driven by robust sales of its attention-deficit/hyperactivity disorder (ADHD) treatment, **AZSTARYS®**. […]

$ZVRA Reports Q4 2025 Revenue Growth Amidst Pipeline Advancements Read More »

$IVVD Reports Strong Q4 2025 Revenue Beat, Positive VYD222 Update

Stock market news /

Key Takeaways Invivyd, Inc. (**$IVVD**) reported **Q4 2025 revenue** of **$25.3 million**, exceeding analyst consensus estimates of $23.5 million, per the Invivyd Q4 2025 Earnings Call Presentation. The company posted an adjusted **net loss** of **-$0.15 per share** for Q4, outperforming analyst expectations of a -$0.20 loss, according to the same presentation. Positive interim data

$IVVD Reports Strong Q4 2025 Revenue Beat, Positive VYD222 Update Read More »

$ATAI Exceeds Q4 2025 Revenue Estimates, Boosts Full-Year Guidance

Stock market news /

Key Takeaways Atea Pharmaceuticals, Inc. (ATAI) reported Q4 2025 revenue of $125 million, surpassing analyst consensus of $118 million, per the company’s earnings call presentation. Non-GAAP diluted earnings per share (EPS) reached $0.15, exceeding expectations of $0.10, according to internal company financial statements. The company initiated a Phase 3 clinical trial for its novel antiviral

$ATAI Exceeds Q4 2025 Revenue Estimates, Boosts Full-Year Guidance Read More »